Camlin Fine Sciences Limited · NSE:CAMLINFINE
Camlin Fine Sciences — Q4 FY25 Earnings Presentation
27 slides from Camlin Fine Sciences's earnings presentation, May 23, 2025
Slide 1: Regulation 30 intimation to stock exchanges
May 23, 2025 To, To, BSE Limited, Listing Department, 25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai- 400051 Ref: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE || Series: EQ Sub: Intimation purs
Slide 2: Camlin Fine Sciences Limited Investor Presentation – May 2025
Camlin Fine Sciences Limited Investor Presentation – May 2025
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Performance Highlights – Q4 & FY25
Performance Highlights – Q4 & FY25 3
Slide 5: FY25 Operational Highlights
FY25 Operational Highlights From Continuing Operations Revenue (Rs. In Mn) EBITDA (Rs. In Mn) • Total Revenue for FY25 improved by 15% to Rs. 16,665 mn on YoY basis 16,131 16,928 1,574 • Adjusted EBITDA for FY25 improved by 13% to Rs. 2,081 mn on YoY basis 978 • EBITDA margin stood at 12.5% for the
Slide 6: Q4 & FY25 Performance Highlights
Q4 & FY25 Performance Highlights From Continuing Operations# Revenue (Rs. In Mn) EBITDA* (Rs. In Mn) PAT (Rs. In Mn) 13.1% 14.4% 13.6% % Margin 4,310 4,375 3,767 622 594 227 195 492 16 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 Q4FY24 Q3FY25 Q4FY25 12.6% 12.5% 16,665 2,081 14,539 1,836 530 494 FY24 F
Slide 7: Operational Revenue Breakup
Operational Revenue Breakup From Continuing Operations# Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) 4,111 8,784 12,605 3,821 11,585 7,474 1,017 976 1,884 1,949 2,900 2,925 Q4FY24 Q4FY25 FY24 FY25 Q4FY24
Slide 8: Regional Highlights
Regional Highlights From Continuing Operations# CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 8,865 4,822 5,062 679 7,733 525 2,726 2,203 1,217 1,178 162 126 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q4FY25 FY24 FY25 Q4FY24 Q4FY25 FY24 FY25 CFS Brazil (Rs. In Mn) CFS North America (Rs. In
Slide 9: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement From Continuing Operations# Particulars (Rs. In Mn) Q4 FY25 Q4 FY24 YoY Q3 FY25 QoQ FY25 FY24 YoY Revenue from Operation 4,374.6 3,766.5 16.1% 4,310.2 1.5% 16,665.3 14,539.1 14.6% Raw material consumption 2,153.0 2,063.7 2,141.1 8,492.6 7,698.5 Employee Cost 501.
Slide 10: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement Particulars (Rs. In Mn) Q4 FY25 Q4 FY24 YoY Q3 FY25 QoQ FY25 FY24 YoY Revenue from Operation 2,726.0 2,203.3 23.7% 2,050.7 32.9% 8,864.9 7,732.6 14.6% Raw material consumption 1,473.5 1,650.1 1,012.9 4,812.6 4,436.7 Employee Cost 188.9 165.4 171.8 724.8 659.5 Other
Slide 11: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (Rs. In Mn) Mar – 25 Mar – 24 Particulars (Rs. In Mn) Mar – 25 Mar - 24 Equity Non-Current assets Equity Share Capital 187.9 167.5 Property, Plant and Equipment 5,925.6 7,122.4 Capital Work-In-Progress 97.3 455.6 Other Equity 8,828.8 8,480.0 Right use of assets
Slide 12: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. In mn) Mar – 25 Mar – 24 Profit Before Tax Continuing operations 494.7 585.9 Discontinued operations (2,075.2) (1,578.4) Net Profit Before Tax (1,580.5) (992.4) Adjustments for: Non-Cash Items / Other Investment or Financial Items 3,013.6 2,540.9 Ope
Slide 13: Company Overview
Company Overview INGREDIENTS- Ce ee ee reer n eee eee
Slide 14: Company Overview
Company Overview FY25 Revenue Mix* ₹ 16,319 mn 23% 100+ 1,250+ Range of Diversified Base of Satisfied Products Customers Worldwide Preferred Partner High Quality & Wide For Customized Shelf-Life Range 54% Solutions Vanillin Manufacturer Among Global 49,000+ Specialty Ingredients Leaders Led by Integ
Slide 15: Product Highlights
Product Highlights FY25 Sales Mix%* Key Products End User Industries Key Brands › TBHQ › Pet Food › Animal Feed Mills Straights 23% › BHA › Livestock Nutrition › Biodiesel › Ascorbyl palmitate (ASP) › Food & Beverages › Aquaculture & Fishmeal › Fish Meal › Rendering Specialty Ingredients › 200+ cust
Slide 16: Innovation at Work
Innovation at Work Process Optimization Initiatives • Vanillin Production Optimization: Continuous improvement at our new Dahej plant, refining processes and setting a future – oriented strategic direction • HQ Derivatives Process: Developed a novel, process with improved selectivity for producing H
Slide 17: Acquisition of Vitafor Invest NV
Acquisition of Vitafor Invest NV • Dresen Quimica SAPI De CV, Mexico has acquired 100% stake in Vitafor Invest Acquisition NV, Belgium and its underlying subsidiaries/associate on June 11, 2024 Details • 100% stake in Target Entity for Cash Consideration of € 1 (Euro One) Key Rationale Brief Backgro
Slide 18: Manufactured In-house
Integration Chain Phenol Hydroquinone Diphenols Catechol Manufactured In-house Performance Performance Specialty Ingredients Chemicals Aroma Ingredients Chemicals Ascorbyl Palmitate1 TBHQ MEHQ Guaiacol Guethol BHA Other derivatives of HQ Veratrole Vanillin Other derivatives of Blends Ethyl Vanillin
Slide 19: ESG
ESG • Main goal by 2030 is to switch to renewable electricity for all manufacturing facilities. Currently, company is exploring different options to achieve this goal Enviro nmen t • Dedicated to sustainability and done few initiatives from reducing food waste to sourcing clean energy • Constantly s
Slide 20: Board of Directors
Board of Directors Name Profile Name Profile › Over three decades of experience in pharmaceuticals and › Managing Director of the MJ Group with over three decades of specialty chemical products including business planning, Ashish Dandekar Amol Shah experience covering human healthcare, F&F compounds
Slide 21: Senior Management Team
Senior Management Team Name › Profile Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information Chairman & Managing Director systems, research & development, product development, and marketing › Holds a BA in Econom
Slide 22: Way Forward
Way Forward Specialty Ingredients Aroma Ingredients • Maintaining market leadership for • Introduce specialized and customized Antioxidants products within the vanillin range, catering to diverse application needs • Increasing focus on high margin blends and additives. These formulations are • Activ
Slide 23: Historical Financial Highlights
Historical Financial Highlights
Slide 24: Historical Financial Highlights
Historical Financial Highlights Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 15.3% 10.8% 12.7% 6.0% 9.3% Margin 16,816 16,131 16,928 654 604 2,131 1,574 398 14,121 1,819 978 530 494 11,871 1,528 14,539 16,665 1,836 2,081 -1,578 -2,075 1,591 -858 -507 -1,049 263 -1,581 FY21 FY22 FY23 FY24 F
Slide 25: Operational Revenue Break-Up
Operational Revenue Break-Up Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) 12,605 11,585 4,576 8,784 9,679 4,111 7,474 3,812 3,821 7,980 2,860 5,103 6,171 4,168 3,311 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY2
Slide 26: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 8,865 4,822 5,062 4,883 7,894 7,733 4,395 6,855 3,762 6,000 3,533 3,198 2,735 679 525 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 CFS Brazil (Rs. In Mn) CFS North America (Rs. In Mn
Slide 27: Thank You !
Thank You ! Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Mr. Santosh Parab- CFO Email – santosh.parab@camlinfs.com santosh.parab@camlinfs.com www.camlinfs.com www.camlinfs.com http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shri